| Ident. | Authors (with country if any) | Title |
|---|
| 000166 (2020) |
Josef S. Smolen [Autriche] ; Robert B M. Landewé [Pays-Bas] ; Johannes W J. Bijlsma [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Andreas Kerschbaumer [Autriche] ; Iain B. Mcinnes [Royaume-Uni] ; Alexandre Sepriano [Pays-Bas] ; Ronald F. Van Vollenhoven [Pays-Bas] ; Maarten De Wit [Pays-Bas] ; Daniel Aletaha [Autriche] ; Martin Aringer [Allemagne] ; John Askling [Suède] ; Alejandro Balsa [Espagne] ; Maarten Boers [Pays-Bas] ; Alfons A. Den Broeder [Pays-Bas] ; Maya H. Buch [Royaume-Uni] ; Frank Buttgereit [Allemagne] ; Roberto Caporali [Italie] ; Mario Humberto Cardiel [Mexique] ; Diederik De Cock [Belgique] ; Catalin Codreanu [Roumanie] ; Maurizio Cutolo [Italie] ; Christopher John Edwards [Royaume-Uni] ; Yvonne Van Eijk-Hustings [Pays-Bas] ; Paul Emery [Royaume-Uni] ; Axel Finckh [Suisse] ; Laure Gossec [France] ; Jacques-Eric Gottenberg [France] ; Merete Lund Hetland [Danemark] ; Tom W J. Huizinga [Pays-Bas] ; Marios Koloumas [Suisse] ; Zhanguo Li [République populaire de Chine] ; Xavier Mariette [France] ; Ulf Müller-Ladner [Allemagne] ; Eduardo F. Mysler [Argentine] ; Jose A P. Da Silva [Portugal] ; Gyula Po R [Hongrie] ; Janet E. Pope [Canada] ; Andrea Rubbert-Roth [Suisse] ; Adeline Ruyssen-Witrand [France] ; Kenneth G. Saag [États-Unis] ; Anja Strangfeld [Allemagne] ; Tsutomu Takeuchi [Japon] ; Marieke Voshaar [Pays-Bas] ; René Westhovens [Belgique] ; Désirée Van Der Heijde [Pays-Bas] | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. |
| 000289 (2019) |
Olafur Sveinsson [Suède] ; Fredrik Piehl [Suède] ; Oskar Aspegren [Suède] ; Max Albert Hietala [Suède] | Successful combined treatment with thymectomy, rituximab and tocilizumab for severe thymoma-associated multi autoimmune syndrome. |
| 000349 (2020) |
Bernhard Hellmich [Allemagne] ; Ana Agueda [Portugal] ; Sara Monti [Italie] ; Frank Buttgereit [Allemagne] ; Hubert De Boysson [France] ; Elisabeth Brouwer [Pays-Bas] ; Rebecca Cassie [Royaume-Uni] ; Maria C. Cid [Espagne] ; Bhaskar Dasgupta [Royaume-Uni] ; Christian Dejaco [Autriche] ; Gulen Hatemi [Turquie] ; Nicole Hollinger [Allemagne] ; Alfred Mahr [France] ; Susan P. Mollan [Royaume-Uni] ; Chetan Mukhtyar [Royaume-Uni] ; Cristina Ponte [Portugal] ; Carlo Salvarani [Italie] ; Rajappa Sivakumar [Inde] ; Xinping Tian [République populaire de Chine] ; Gunnar Tomasson [Islande] ; Carl Turesson [Suède] ; Wolfgang Schmidt [Allemagne] ; Peter M. Villiger [Suisse] ; Richard Watts [Royaume-Uni] ; Chris Young [Royaume-Uni] ; Raashid Ahmed Luqmani [Royaume-Uni] | 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. |
| 000400 (2019) |
Thomas Frisell [Suède] ; Johan Askling [Suède] | Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply. |
| 000470 (2019) |
C. Turesson [Suède] ; O. Börjesson [Suède] ; K. Larsson [Suède] ; A J Mohammad [Suède] ; A. Knight [Suède] | Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis. |
| 000471 (2019) |
Thomas Frisell [Suède] ; Johan Askling [Suède] | Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply. |
| 000523 (2019) |
Thomas Frisell [Suède] ; Mats Dehlin ; Daniela Di Giuseppe [Suède] ; Nils Feltelius ; Carl Turesson ; Johan Askling [Suède] | Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. |
| 000541 (2019) |
Kathrine Lederballe Gr N [Oman] ; Elizabeth V. Arkema [Suède] ; Bente Glintborg [Danemark] ; Frank Mehnert [Danemark] ; Mikkel Stergaard [Danemark] ; Lene Dreyer [Danemark] ; Mette N Rgaard [Danemark] ; Niels Steen Krogh [Danemark] ; Johan Askling [Suède] ; Merete Lund Hetland [Danemark] | Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. |
| 000921 (2018) |
Thomas Frisell [Suède] ; Eva Baecklund [Suède] ; Karin Bengtsson [Suède] ; Daniela Di Giuseppe [Suède] ; Helena Forsblad-D'Elia [Suède] ; Johan Askling [Suède] | Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. |
| 000A01 (2017) |
Hjalmar Wadström [Suède] ; Thomas Frisell [Suède] ; Johan Askling [Suède] | Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. |
| 000A28 (2017) |
Olafur Sveinsson [Suède] ; Mathias Granqvist [Suède] ; Yngve Forslin [Suède] ; Kaj Blennow [Suède] ; Henrik Zetterberg [Royaume-Uni] ; Fredrik Piehl [Suède] | Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis. |
| 000B01 (2017) |
Takashi Matsuwaki [Japon] ; Kiseko Shionoya [Suède] ; Robert Ihnatko [Suède] ; Anna Eskilsson [Suède] ; Shigeru Kakuta [Japon] ; Sylvie Dufour [France] ; Markus Schwaninger [Allemagne] ; Ari Waisman [Allemagne] ; Werner Müller [Royaume-Uni] ; Emmanuel Pinteaux [Royaume-Uni] ; David Engblom [Suède] ; Anders Blomqvist [Suède] | Involvement of interleukin-1 type 1 receptors in lipopolysaccharide-induced sickness responses. |
| 000B61 (2017) |
Dagur Ingi Jonsson [Suède] ; Ritva Pirskanen [Suède] ; Fredrik Piehl [Suède] | Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. |
| 000B74 (2017) |
Gerd R. Burmester [Allemagne] ; William F. Rigby [États-Unis] ; Ronald F. Van Vollenhoven [Suède] ; Jonathan Kay [États-Unis] ; Andrea Rubbert-Roth [Allemagne] ; Ricardo Blanco [Espagne] ; Alysha Kadva [États-Unis] ; Sophie Dimonaco [Royaume-Uni] | Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. |
| 000B76 (2017) |
Daniel Glinatsi [Danemark] ; Marte S. Heiberg [Norvège] ; Anna Rudin [Suède] ; Dan Nordström [Finlande] ; Espen A. Haavardsholm [Norvège] ; Bjorn Gudbjornsson [Islande] ; Mikkel Stergaard [Danemark] ; Till Uhlig [Norvège] ; Gerdur Grondal [Islande] ; Kim H Rslev-Petersen [Danemark] ; Ronald Van Vollenhoven [Suède] ; Merete L. Hetland [Danemark] | Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study. |
| 000C11 (2017) |
Josef S. Smolen [Autriche] ; Robert Landewé [Pays-Bas] ; Johannes Bijlsma [Pays-Bas] ; Gerd Burmester [Allemagne] ; Katerina Chatzidionysiou [Suède] ; Maxime Dougados [France] ; Jackie Nam [Royaume-Uni] ; Sofia Ramiro [Pays-Bas] ; Marieke Voshaar [Pays-Bas] ; Ronald Van Vollenhoven [Pays-Bas] ; Daniel Aletaha [Autriche] ; Martin Aringer [Allemagne] ; Maarten Boers [Pays-Bas] ; Chris D. Buckley [Royaume-Uni] ; Frank Buttgereit [Allemagne] ; Vivian Bykerk [États-Unis] ; Mario Cardiel [Mexique] ; Bernard Combe [France] ; Maurizio Cutolo [Italie] ; Yvonne Van Eijk-Hustings [Pays-Bas] ; Paul Emery [Pays-Bas] ; Axel Finckh [Suisse] ; Cem Gabay [Suisse] ; Juan Gomez-Reino [Espagne] ; Laure Gossec [France] ; Jacques-Eric Gottenberg [France] ; Johanna M W. Hazes [Pays-Bas] ; Tom Huizinga [Pays-Bas] ; Meghna Jani [Royaume-Uni] ; Dmitry Karateev [Russie] ; Marios Kouloumas [Suisse] ; Tore Kvien [Norvège] ; Zhanguo Li [République populaire de Chine] ; Xavier Mariette [France] ; Iain Mcinnes [Royaume-Uni] ; Eduardo Mysler [Argentine] ; Peter Nash [Australie] ; Karel Pavelka [République tchèque] ; Gyula Po R [Hongrie] ; Christophe Richez [France] ; Piet Van Riel [Pays-Bas] ; Andrea Rubbert-Roth [Allemagne] ; Kenneth Saag [États-Unis] ; Jose Da Silva [Portugal] ; Tanja Stamm [Autriche] ; Tsutomu Takeuchi [Japon] ; René Westhovens [Belgique] ; Maarten De Wit [Pays-Bas] ; Désirée Van Der Heijde [Pays-Bas] | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. |
| 000C31 (2017) |
Tanja Schj Dt J Rgensen [Danemark] ; Carl Turesson [Suède] ; Meliha Kapetanovic [Suède] ; Martin Englund [Suède] ; Aleksandra Turkiewicz [Suède] ; Robin Christensen [Danemark] ; Henning Bliddal [Danemark] ; Pierre Geborek [Suède] ; Lars Erik Kristensen [Danemark] | EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry. |
| 000C59 (2017) |
Robert J. Moots [Royaume-Uni] ; Anthony Sebba [États-Unis] ; William Rigby [États-Unis] ; Andrew Ostor ; Benjamin Porter-Brown [Royaume-Uni] ; Francis Donaldson [Royaume-Uni] ; Sophie Dimonaco [Royaume-Uni] ; Andrea Rubbert-Roth [Allemagne] ; Ronald Van Vollenhoven [Suède] ; Mark C. Genovese [États-Unis] | Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. |
| 000E30 (2017) |
Louise K. Mercer [Royaume-Uni] ; Johan Askling [Suède] ; Pauline Raaschou [Suède] ; William G. Dixon [Royaume-Uni] ; Lene Dreyer [Danemark] ; Merete Lund Hetland [Danemark] ; Anja Strangfeld [Allemagne] ; Angela Zink [Allemagne] ; Xavier Mariette [France] ; Axel Finckh [Suisse] ; Helena Canhao [Portugal] ; Florenzo Iannone [Italie] ; Jakub Zavada [République tchèque] ; Jacques Morel [France] ; Jacques-Eric Gottenberg [France] ; Kimme L. Hyrich [Royaume-Uni] ; Joachim Listing [Allemagne] | Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. |
| 000F09 (2016) |
Alexei A. Grom [États-Unis] ; Annacarin Horne [Suède] ; Fabrizio De Benedetti [Italie] | Macrophage activation syndrome in the era of biologic therapy. |
| 000F38 (2016) |
Anders Gülfe [Suède] ; Johan K. Wallman [Suède] ; Lars Erik Kristensen [Danemark] | EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden. |
